Biosyent Inc. (CVE:RX) shares rose 1.9% on Wednesday . The company traded as high as C$6.36 and last traded at C$6.36, approximately 500 shares changed hands during mid-day trading. A decline of 94% from the average daily volume of 8,444 shares. The stock had previously closed at C$6.24.

RX has been the subject of a number of research reports. Bloom Burton upgraded shares of Biosyent from an “accumulate” rating to a “buy” rating in a report on Monday, August 26th. Cormark dropped their price objective on shares of Biosyent from C$8.25 to C$7.50 in a report on Monday, August 26th. Finally, Raymond James dropped their price objective on shares of Biosyent from C$7.50 to C$6.00 and set a “market perform” rating for the company in a report on Monday, August 26th.

The business’s fifty day moving average is C$6.08 and its 200-day moving average is C$6.96. The firm has a market cap of $87.58 million and a P/E ratio of 19.81.

Biosyent (CVE:RX) last issued its quarterly earnings data on Friday, August 23rd. The company reported C$0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.11 by C($0.06). The company had revenue of C$5.16 million for the quarter, compared to analyst estimates of C$6.35 million. Equities research analysts anticipate that Biosyent Inc. will post 0.37 EPS for the current fiscal year.

About Biosyent (CVE:RX)

BioSyent Inc, a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer.

Read More: How does a 12b-1 fee affect fund performance?

Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with MarketBeat.com's FREE daily email newsletter.